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Abstract Alemtuzumab (LemtradaTM) is a humanized
monoclonal antibody approved in more than 50 countries.
Within the European Union, alemtuzumab is indicated for
the treatment of adult patients with relapsing-remitting
multiple sclerosis (RRMS) with active disease defined by
clinical or imaging features; in the USA, the indication
states that alemtuzumab should generally be reserved for
the treatment of patients with relapsing forms of multiple
sclerosis who have had an inadequate response to two or
more disease-modifying therapies (DMTs). In clinical tri-
als, alemtuzumab demonstrated efficacy in treatment-naı¨ve
patients with active RRMS and those relapsing on prior
DMTs, with a consistent and manageable safety and tol-
erability profile. The European Union indication provides
physicians with significant flexibility regarding treatment
decisions, affording the opportunity for individualized
treatment. Thus, alemtuzumab may be an appropriate
treatment choice across a broad range of patients with
RRMS, including, for example, treatment-naı¨ve patients
with active disease, patients with highly active disease, or
for patients relapsing on prior DMTs. There are several
practicalities to consider when using alemtuzumab,
including the unique dosing regimen, administered via
intravenous infusion on 5 consecutive days at baseline and
on 3 consecutive days 12 months later, and as-needed
retreatment (3 consecutive days at least 12 months after the
last course) in cases of disease recurrence. Additionally,
routine monthly monitoring is required for up to 48 months
after the last infusion to promptly identify potentially
serious autoimmune adverse events. Given these consid-
erations, it is beneficial to gain insight into how alem-
tuzumab is being used in the real-world clinical setting.
Here, we report recommendations from European multiple
sclerosis experts regarding best practices for alemtuzumab
treatment, including management of adverse events and
compliance with ongoing safety monitoring requirements.
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Key Points
In the European Union (EU), alemtuzumab is
indicated for adult patients with relapsing-remitting
multiple sclerosis, with active disease defined by
clinical or imaging features. It can be considered as
an initial therapeutic for treatment-naı¨ve patients
with active disease and for patients relapsing on prior
disease-modifying therapy.
Healthcare providers should adhere to the
alemtuzumab EU label, which gives a broad
definition of patient eligibility for treatment;
alemtuzumab is not suitable for patients with
inactive relapsing-remitting multiple sclerosis, those
stable on current therapy, or patients with
progressive multiple sclerosis.
The Risk Management Program in the EU and other
countries in addition to the Risk Evaluation and
Mitigation Strategy in the USA are critical to ensure
early detection of potential adverse events arising
during and after alemtuzumab treatment and to
ensure compliance with monitoring requirements.
Data from an ongoing extension study, from real-
world studies, and from post-marketing safety data
will also be important to establish long-term safety
of alemtuzumab treatment.
1 Introduction
Alemtuzumab is a humanized monoclonal antibody
approved in more than 50 countries [1], including the
European Union (EU) for the treatment of adult patients
with active relapsing-remitting multiple sclerosis (RRMS)
defined by clinical or imaging features, and the USA for
the treatment of relapsing forms of multiple sclerosis (MS)
[2, 3]. In the USA, the indication for alemtuzumab states
that it should generally be reserved for patients who have
experienced an inadequate response to two or more dis-
ease-modifying therapies (DMTs) [3].
Alemtuzumab selectively targets CD52, a protein
expressed at high levels on the surface of T and B lym-
phocytes but at lower levels on natural killer cells and other
cell types involved in innate immunity, leading to a
selective depletion of circulating T and B cells [4, 5],
thereby decreasing inflammatory MS disease activity.
Following treatment with alemtuzumab, T and B lympho-
cytes repopulate in a distinctive pattern over time that
results in a rebalancing of the immune system over a period
of 3–12 months [5, 6].
This mechanism allows for a unique dosing regimen of
12-mg intravenous infusions on 5 consecutive days at
baseline and on 3 consecutive days 12 months later and
may also account for the observed durable efficacy in the
absence of continuous treatment, with most patients only
requiring these two initial treatment courses [2, 7, 8].
The safety and efficacy of alemtuzumab have been assessed
in phase II and III clinical trials in treatment-naı¨ve patients
(CAMMS223 [NCT00050778]; CARE-MS I [NCT0053034
8]), in patients with active disease despite treatment with
another DMT (CARE-MS II [NCT00548405]) (Table 1), and
in extension (NCT00930553) and long-term follow-up studies
(NCT02255656) that include patients from the phase II, III, and
IV trials. The phase II and III studies all included an active
comparator arm in which patients were treated with subcuta-
neous (SC) interferon b-1a (IFNb-1a), a DMT with an estab-
lished efficacy across standard endpoints in RRMS [9–13]. In
CAMMS223 and CARE-MS II, two doses (12 and 24mg/day)
of alemtuzumabwere evaluated; however, discussion of data in
this article will be restricted to the 12-mg dose as this is the
approved and commercially available dose [2, 9, 12].
2 Clinical Trial Experience with Alemtuzumab
2.1 Efficacy Data from Clinical Trials
As discussed, in the three pivotal clinical trials, SC IFNb-
1a was included as an active comparator (Table 1); there-
fore, all subsequent comparisons relate to outcomes for
alemtuzumab vs. SC IFNb-1a. Across the CAMMS223 and
CARE-MS I and II trials, alemtuzumab significantly
reduced the annualized relapse rate (AAR) (co-primary
endpoint) and was also associated with significant reduc-
tions in 6-month confirmed disability worsening (CDW,
co-primary endpoint) in CAMMS223 [9] and CARE-MS II
[12], and a non-significant 30% reduction in CARE-MS I
[11].
In addition, in a recent analysis of data from the
CAMMS223 study, alemtuzumab had greater efficacy than
SC IFNb-1a at month 36 in each of the functional systems
that make up the Expanded Disability Status Scale (EDSS)
score, with the greatest effects being observed in the sen-
sory, pyramidal, and cerebellar systems, which are thought
to drive CDW in RRMS [16]. Across all trials, alem-
tuzumab also demonstrated improvements in several
magnetic resonance imaging (MRI) outcomes (lesion vol-
ume/load, and brain atrophy) [9, 11, 12].
In CARE-MS I and II, alemtuzumab-treated patients
demonstrated a reduced rate of brain atrophy, as deter-
mined by median yearly percentage change in brain
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parenchymal fraction over 2 years [11, 17], reaching sig-
nificance in both CARE-MS I (42% reduction, p\0.0001)
and CARE-MS II (24% reduction, p = 0.0121) compared
with SC IFNb-1a at year 2. Furthermore, durable efficacy
(AAR, disability, and MRI outcomes, including lesions and
brain atrophy) was demonstrated throughout the extension
studies [7, 8, 13, 17–19], with the majority of patients
(68–94%) not requiring retreatment with alemtuzumab or
another DMT [17, 20]. Key efficacy outcomes from the
clinical trial program trials are summarized in Table 2.
2.2 Safety Data from Clinical Trials
Alemtuzumab has a consistent and manageable safety and
tolerability profile as demonstrated across individual clin-
ical trials [9, 11, 12]), enrolling a total of 1694 patients.
Furthermore, a similar safety and tolerability profile was
also documented with a long-term follow-up (up to 5 years)
in the extension studies [7, 8, 13].
Nevertheless, several adverse events (AEs) of interest
have been reported (Table 3). The most frequently reported
AEs in clinical trials were infusion-associated reactions
(IARs), experienced by[90% of patients, which peaked
immediately following the initial alemtuzumab course and
then decreased with subsequent courses [21, 22]. Few
(B3%) serious IARs were reported [9, 11–13, 21, 23, 24].
The incidence of infections (which were mainly mild to
moderate in severity) was greatest during the first month
following infusion in all three trials [25] but was lower in
the CAMMS223 and CARE-MS extensions compared with
the core studies, suggesting a reduction in infection risk
over time [11–13, 15].
Thyroid disease was the most common autoimmune
event; however,\1% of patients experienced serious thy-
roid AEs [2, 9, 13, 26, 27]. Immune thrombocytopenic
purpura (ITP) was identified as a potential risk in the
CAMMS223 study, initially reported in six patients,
including the fatal index case in a patient receiving alem-
tuzumab 24 mg [9, 28, 29]. Across all clinical trials, ITP
incidence was 2% in patients receiving alemtuzumab 12 or
24 mg (1.6% in patients receiving alemtuzumab 12 mg)
[11–13, 29].
In response to the index case and other autoimmune
events, enhanced monitoring and patient education was
Table 1 Alemtuzumab clinical trial program
CAMMS223a [2, 9, 14] CARE-MS I [2, 11, 14] CARE-MS IIa [2, 12, 14]
Patients with active RRMS who were treatment naı¨ve Patients with active RRMS who relapsed on
prior DMT
Study duration: 3 years Study duration: 2 years Study duration: 2 years
SC IFNb-1a
(44 lg TIW)
N = 111
Alemtuzumab
(12 mg/day)
N = 112
SC IFNb-1a
(44 lg TIW)
N = 187
Alemtuzumab
(12 mg/day)
N = 376
SC IFNb-1a
(44 lg TIW)
N = 202
Alemtuzumab
(12 mg/day)
N = 426
MRI criteria: diagnosis per McDonald 2001
criteria, including brain MRI; C1 Gd? lesion
on any of B4 brain scans during B3-month
run-in period (including baseline scan)
MRI criteria: diagnosis per McDonald 2005
criteria; brain MRI scan demonstrating white
matter lesions attributable to MS (within 5
years of screening)
MRI criteria: diagnosis per McDonald 2005
criteria; white matter lesions attributable to
MS and at least one of the following: C9 T2
lesions C3 mm, any axis; a Gd? lesion C3
mm, any axis, with C1 brain T2 lesion;
spinal cord lesion with C1 brain T2 lesion
Active MS: C2 relapses in the prior 2 years
and C1 Gd? MRI lesion at screening
Active MS: C2 relapses in the prior 2 years,
with C1 relapse occurring in the year prior
to study entry
Active MS: C2 relapses in the prior 2 years,
with C1 relapse occurring in the year prior
to study entry and C1 relapse occurring
during prior treatmentb
Mean age: 32 years Mean age: 33 years Mean age: 35 years
EDSS range: 0.0–3.0 (mean 2.0)c EDSS range: 0.0–3.0 (mean 2.0)d EDSS range: 0.0–5.0 (mean 2.7)d
Mean/median time since first MS episode: 1.4/
1.3 years
Mean/median time since first MS episode: 2.0/
1.6 years
Mean/median time since first MS episode: 4.5/
3.8 years
Retreatment criteria for CAMMS223 (Sanofi Genzyme, data on file) and CARE-MS extensions [15]: C1 relapse or C2 new or enlarging T2 and/
or Gd? brain or spinal lesions, C12 months since the second alemtuzumab course
DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, Gd? gadolinium-enhancing, IFN interferon, MRI magnetic resonance
imaging, MS multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, SC subcutaneous, TIW three times per week
a A 24-mg/day treatment arm was included in these studies
b Treatment with IFNb or glatiramer acetate for C6 months
c At screening and baseline visits
d At screening
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introduced for ongoing trials, which resulted in early
identification and management of ITP cases, as well as
other autoimmune events (thyroid dysfunction and
glomerulonephropathy) in the clinical trials and improved
patient outcomes. Subsequently, a Risk Management Pro-
gram (RMP) and a Risk Evaluation and Mitigation Strategy
(REMS) [30] were implemented to ensure early detection
of potential AEs in real-world clinical practice. Across the
clinical development program, there were four reported
cases of immune nephropathy, including one case of anti-
glomerular basement membrane (anti-GBM) disease (in
CAMMS223) reported 39 months after the second alem-
tuzumab course [13, 31].
A single fatal case of progressive multifocal leukoen-
cephalopathy (PML) has been reported in a patient who
switched from natalizumab to alemtuzumab. The PML
diagnosis was not made until after the patient had received
the first course of alemtuzumab; however, retrospective
analysis of the MRI data showed that the onset of PML
predated alemtuzumab treatment and, therefore, was
attributed to natalizumab treatment (Sanofi Genzyme, data
on file). The efficacy and safety outcomes from the alem-
tuzumab clinical trials have also been extensively reported
in the literature; for further information, we refer the reader
to these publications [9, 11–13, 32].
2.3 Additional Long-Term Experience
with Alemtuzumab
A long-term, investigator-led, observational cohort study
has also demonstrated the long-term efficacy and safety of
alemtuzumab in patients with active RRMS [37]. In this
study, 87 patients (39% having received a prior DMT) were
followed for up to 12 years (median follow-up 7 years).
The majority of patients (68%) experienced an improve-
ment or stabilization of disability (based upon 6-month
CDW) compared with baseline. Retreatment was permitted
in the event of a relapse with 52% of patients receiving
only the initial two courses, with the remainder receiving
three (36%), four (8%), or five (1%) courses. The
remaining patients (3%) received only a single treatment
course [37].
3 Use of Alemtuzumab in a Real-World Clinical
Setting
Real-world data indicate that, in the majority of patients
with active or highly active RRMS, alemtuzumab treat-
ment is associated with disease stabilization [37, 38]. There
is, however, some debate regarding which patients would
benefit most from alemtuzumab treatment. The following
sections of this article present the opinions and recom-
mendations of European MS experts with regard to iden-
tifying the most appropriate patients for alemtuzumab
treatment and best practices for treatment and monitoring.
3.1 Alemtuzumab Indication
The EU indication for alemtuzumab states that alem-
tuzumab is suitable for ‘‘adult patients with RRMS with
active disease defined by clinical or imaging features’’ [2].
This represents an apparent shift from previous regulatory
labeling on the eligibility of patients for a particular DMT
and potentially allows physicians to use alemtuzumab as a
first-line treatment choice in appropriate patients. EU
indications for other DMTs (e.g., fingolimod, natalizumab)
are more restrictive, requiring evidence of a specified level
of MRI activity, in addition to clinical activity before
treatment initiation. Fingolimod and natalizumab are
therefore recommended for use in patients with highly
active disease who have breakthrough disease activity on a
Table 3 Most common AEs
observed in clinical trials of
alemtuzumab 12 mg
CAMMS223
[9, 10]
N = 108
CARE-MS I
[11]
N = 376
CARE-MS II
[12]
N = 435
AEs occurring in[10% of patients, n (%)
Infusion-associated reactions 106 (98) 338 (90) 393 (90)
Infection 71 (66) 253 (67) 334 (77)
Upper respiratory tract 48 (44) 57 (15) 71 (16)
Urinary tract 10 (9) 64 (17) 93 (21)
Autoimmunity
Any autoimmune thyroid-associated event 28 (26) 68 (18) 69 (16)
Blood and lymphatic system disorders NR 66 (18) 59 (14)
Lymphopenia NR 26 (7) 23 (5)
Leukopenia NR 11 (3) NR
AEs adverse events, NR not reported
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previous DMT (i.e., as a second-line therapy) or in those
with more rapidly evolving severe RRMS [39, 40].
3.2 Is There a Requirement for Specific Patient
Profiles?
The EU indication for alemtuzumab may provide pre-
scribing physicians with certain challenges when deciding
which patients are most suitable for treatment, although it
also provides physicians with flexibility, allowing them to
use their own clinical experience and judgment to make an
informed decision regarding what constitutes active disease
and to provide individualized treatment choices in collab-
oration with their patients. Clinical experience may be
more valuable than rigid treatment guidelines, which
attempt to define specific patient profiles for treatment
eligibility. Furthermore, defining a single specific patient
profile for alemtuzumab may not be helpful as this may
unintentionally restrict the use of alemtuzumab in certain
patients, particularly given that alemtuzumab efficacy has
been demonstrated in a broad range of patients and that
subgroup analyses have shown that the effects of alem-
tuzumab remain consistent across most demographic and
disease characteristic subgroups [41–43].
Therefore, further studies are required to elucidate the
variability and durability of response in patients treated
with alemtuzumab to identify reliable biomarkers or clin-
ical characteristics that can assist in the management of MS
and further inform treatment decisions. Recently, several
groups have investigated the prognostic value of peripheral
CD4? lymphocyte cell count recovery as a potential bio-
marker to identify patients who might benefit from
retreatment with an additional course of alemtuzumab,
although the evidence is conflicting in this regard [44–46].
3.3 Personal Experience with Alemtuzumab
in Routine Clinical Practice
In the absence of specific patient profiles and validated
biomarkers, personal clinical experience will inevitably
influence alemtuzumab-related treatment decisions. Col-
lectively, we have treated 181 patients with alemtuzumab,
either as a first-line or as an escalation therapy in patients
with breakthrough disease activity on a previous DMT
(Table 4).
Most of our patients initiated treatment with alem-
tuzumab owing to breakthrough disease (i.e., having only a
partial response to, or not responding to, other therapies).
In general, these patients had experienced one or more
relapses within the previous 12 months and demonstrated
recent inflammatory disease activity (as evidenced either
by gadolinium enhancement (Gd?) or by an obvious
increase in T2 lesion load) on a brain MRI. Thus, alem-
tuzumab use in this group of patients was consistent with a
treatment escalation paradigm. There was a consensus that
more favorable treatment outcomes are typically observed
in these patients if alemtuzumab treatment can be initiated
early on in the disease course, particularly in patients who
are younger, have highly active disease, and have low
levels of disability at the start of treatment. Nevertheless, in
clinical practice, we have also found alemtuzumab is effi-
cacious in patients with already accumulating disability,
particularly when used as a rescue therapy to stabilize
disease and prevent further disability worsening if inflam-
matory disease activity (either clinically or on MRI) is still
overt. We, therefore, recommend the use of alemtuzumab
in patients with active RRMS, regardless of their level of
disability.
However, 15% of our patients represented a very
important treatment group, namely those who were treat-
ment naı¨ve but who presented with early, highly active
disease. Compared with patients receiving alemtuzumab as
an escalation therapy, these patients were generally
younger and had a shorter, but more active disease course,
usually with two or more relapses in the preceding 3–6
months (cluster of relapses). We feel that alemtuzumab
may represent an effective treatment option in treatment-
naı¨ve patients with rapidly evolving MS (or a clinical
relapse accompanied by an increase in the number of T2
lesions and/or ongoing evidence of Gd? T1 lesions), and, as
experience grows and the favorable outcomes associated
with early intervention with alemtuzumab become evident,
alemtuzumab use in this patient population will increase. In
CARE-MS I, alemtuzumab significantly reduced the rate of
Table 4 Summary of author
experiences with alemtuzumab
National approval/reimbursement period September 2013–May 2015
Patients treated, N 181
Female, n (%) 129 (71)
Age, mean (range), years 35 (17–66)
Alemtuzumab as:
First-line therapy, n (%) 27 (15)
Escalation therapy, n (%) 154 (85)
Data provided courtesy of the authors and represents a summary of the experiences in Austria, Finland,
Germany, Ireland, Italy, Norway, and Spain
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brain volume loss in treatment-naı¨ve patients with MS by
42% compared with SC IFNb-1a [34], and, given the
correlation between brain volume loss and disability and
cognitive worsening [47, 48], early treatment with alem-
tuzumab may be more favorable than delaying treatment
(discussed in Sect. 3.4). Indeed, we feel that initiating
alemtuzumab in treatment-naı¨ve patients may be advanta-
geous, as lymphocyte levels have not been affected by use
of prior DMTs.
In our experience, alemtuzumab has a place in routine
clinical practice for the treatment of patients relapsing on
prior treatments, as well as those who are treatment naı¨ve.
Postponing treatment in favor of escalating patients
through alternative DMTs, in effect retaining alemtuzumab
as a last resort, is not advised, and we feel that initiating
alemtuzumab as soon as possible, particularly in patients
with low levels of disability, will be associated with the
most favorable outcomes.
3.4 Alemtuzumab Early in Multiple Sclerosis
The importance of treating MS early in the disease course
to prevent inflammatory processes that lead to irreversible
brain loss is well established [49–52]. Traditionally, the
treatment paradigm is one of escalation therapy, during
which drugs with greater efficacy (often with distinct
mechanisms of action) but with increasing risk are used
as disease progresses, with the most efficacious drugs
(e.g., natalizumab, often considered following failure of
one or more DMTs [53, 54]) used as the last line of
therapy. However, data from alemtuzumab clinical studies
[9, 11–13], coupled with its indication in the EU [2],
afford physicians the opportunity to start alemtuzumab
treatment in patients with active MS early in the disease
course to prevent potentially avoidable CNS damage and
provide the patient with the best opportunity for favorable
treatment outcomes. This may be particularly important
for patients with active MS with poor prognostic signs,
for example, patients presenting with motor, cerebellar, or
sphincter involvement at onset or those experiencing
frequent relapses with poor recovery during the early
years of their disease [55, 56]. The benefits of early
intervention with other DMTs have been widely reported;
for example, in the pivotal 2-year SC IFNb-1a study
(PRISMS) and its 2-year extension (PRISMS-4), patients
who started treatment early had improved clinical out-
comes compared with patients whose treatment was
delayed [57, 58]. These observations have been confirmed
in long-term follow-up studies [59–61]. Early intervention
is thought to address the inflammatory component of the
disease, thereby reducing development of further CNS
pathology [53, 62]. Aggressive therapy early on in the
disease course may provoke an immunological reset and
may, therefore, favorably affect long-term disease pro-
gression [53].
However, the concept of early treatment of active dis-
ease with an immunomodulatory drug such as alem-
tuzumab, believed to rebalance the immune system, is not
yet fully established and would represent a significant
change in mindset for some physicians. In some European
specialist MS centers, patients with highly active or rapidly
evolving severe RRMS are already considered for first-line
treatment with fingolimod or natalizumab (both considered
typically second-line therapies in the EU), and, as noted
above, alemtuzumab was used as a first-line therapy in 15%
of all alemtuzumab-treated patients in our experience
(Table 4). These observations perhaps indicate that MS
treatment may be moving into a new era, away from the
escalation paradigm and toward more robust early treat-
ment of active disease.
3.5 Switching to Alemtuzumab from Prior Disease-
Modifying Therapies
The efficacy of alemtuzumab in patients with active disease
who had relapsed on prior DMTs is of particular clinical
relevance; in such cases, switching therapies should be
considered urgently to bring MS activity under control. As
discussed briefly above (Sect. 2.1, Table 2), the CARE-MS
II study demonstrated superior efficacy with alemtuzumab
vs. SC IFNb-1a in patients with active disease who had
relapsed on prior DMTs [12]. The opportunity to switch
therapies may be particularly important for certain patient
subgroups. For example, patients receiving natalizumab
therapy for over 2 years and/or who are positive for anti-
John Cunningham virus (anti-JCV) antibodies, as well as
those having previously received other immunosuppressive
medications, are at increased risk of developing PML and
may require an alternative DMT [63]. Here, too, alem-
tuzumab may provide a treatment alternative option.
However, transitioning from one particular DMT to
another can be complex, and a washout period may be
required in certain circumstances. Treatment cessation
guidelines and recommended washout periods are some-
times provided within the respective label of each DMT
(Table 5), although there are currently no recommenda-
tions for transitioning to alemtuzumab from these indi-
vidual DMTs. However, in the CARE-MS II extension,
patients who switched from SC IFNb-1a to alemtuzumab
were not required to undergo a washout period. Therefore,
it is often unclear for which treatment transitions a washout
period is required, how long it should be, or what long-term
safety surveillance procedures should be implemented [53].
Nevertheless, as with other immunomodulatory therapies,
concomitant treatment, including initiation of alem-
tuzumab within the washout period of the previous DMT,
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is not advisable, owing to the potential risk of carry-over
PML from previous treatment and additive effects on the
immune system [2]. Consequently, it is important to con-
sider the half-life as well as the mechanism of action
(MoA) of the previous DMT when transitioning to alem-
tuzumab [53].
Despite the absence of specific guidance for switching to
alemtuzumab from the DMTs listed in Table 5, there are
some considerations that may help guide switching in
clinical practice. The proposed MoA of fingolimod (pre-
venting lymphocyte egress from peripheral lymphoid
organs) results in low levels of circulating lymphocytes
[69]. Therefore, it may be advisable to wait until lym-
phocyte counts begin to recover before initiating treatment
with a DMT, such as alemtuzumab, particularly given that
the proposed MoA of alemtuzumab in MS requires effec-
tive targeting of circulating T and B cells, leading to their
depletion and subsequent repopulation [4, 5, 64]. Indeed, a
recent report demonstrated clinical and MRI disease
activity in alemtuzumab-treated patients who had switched
from fingolimod but for whom a potentially insufficient
washout period following fingolimod cessation had been
used, resulting in lymphocyte counts below normal levels
at the time of alemtuzumab treatment. The authors
hypothesized that the sequestration of lymphocytes in
lymph nodes, owing to the mechanism of action of fin-
golimod, coupled with an inadequate washout period
(median 6 weeks, range 4–10 weeks) may have reduced the
effectiveness of alemtuzumab [70].
By contrast, the proposed MoA of dimethyl fumarate
(DMF) (activation of the nuclear factor erythroid 2-related
factor 2) would generally not predict any issues with rapid
transition to another therapy, although DMF has also been
shown to have a lymphopenic effect in certain patient
populations. Thus, as for fingolimod, a washout period
might be advisable when transitioning to alemtuzumab
[64, 71]. Unfortunately, for both fingolimod and DMF, the
time period over which lymphocytes return to normal is
variable and can take many weeks, during which time the
patient is at risk of relapse [64].
Teriflunomide is also associated with a reduction
(*15%, mean within normal limits) in lymphocytes and
neutrophil counts within the first 3 months following
treatment; mean lymphocyte and neutrophil counts then
remain within the normal range for white blood cell counts
(3.8–10.7 9 109/L) during treatment [72]. Patients receiv-
ing teriflunomide have the opportunity to undergo an
accelerated elimination procedure, which can reduce
plasma levels by [96% in 11 days [66, 73], potentially
allowing the initiation of alemtuzumab relatively quickly
after stopping teriflunomide.
By contrast, natalizumab does not reduce circulating
lymphocyte counts, rather it blocks their entry to the CNS
resulting in only mild lymphocytosis [64, 74], and there
may be limited benefit in delaying initiating treatment with
another DMT following natalizumab discontinuation [64].
In fact, it has been suggested that starting a new treatment
immediately after stopping natalizumab (i.e., no a washout
period) may be preferable because the risk of developing
PML, even in anti-JCV antibody-positive patients, is lower
than the risk of a severe relapse [75, 76]. In CARE-MS II,
patients previously treated with natalizumab (3%) under-
went a 6-month washout period before starting alem-
tuzumab [12]. In real-world clinical settings, and, in
Table 5 General guidance for therapy cessation for common DMTs
Interferons, glatiramer
acetate
No specific guidance for cessation of therapya
No washout period recommended based upon the mechanism of action [64]
Teriflunomide An AEP is available if rapid removal of teriflunomide from the circulation is desired [65]
AEP will reduce plasma concentrations to 0.02 mg/L in 11 days. Complete elimination requires 8 months to 2 years in
the absence of AEP [65, 66]
Dimethyl fumarate No specific guidance for cessation of therapy or requirement for washout [67]
Fingolimod A 6-week treatment-free period is required to clear fingolimod from circulation [39]
Natalizumab A washout period might be appropriate as the pharmacodynamic effects of natalizumab last for approximately 12
weeks following the last dose [40]
Daclizumab Washout period of 4 weeks is recommendedb [68]
Rituximab/ocrelizumabc Washout period of 6 months is recommendedb [68]
AEP accelerated elimination procedure, DMTs disease-modifying therapies, EU European Union, FACS fluorescence-activated cell sorting, IFN
interferon, MS multiple sclerosis, SC subcutaneous
a In CARE-MS II [12], no washout period was required for patients switching from SC IFNb-1a to alemtuzumab
b Washout guidance is based on cited sources along with the expert opinion of the authors
c Ocrelizumab is not yet approved for the treatment of MS in the EU
In all cases, the immune competence (including FACS analysis for B cells in the case of rituximab/ocrelizumab) should be confirmed before
initiating alemtuzumab
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contrast with clinical studies, it is likely that a washout
period of no more than 2 months following natalizumab
discontinuation would be desirable owing to the risk of
rebound disease [64, 76, 77]. Indeed, there are suggestions
that use of a washout period when switching from natal-
izumab may do more harm than good [78].
In this regard, long-term real-world data would be of
immense value in providing additional information on
switching strategies between different DMTs. A recent
real-world switching study demonstrated that in the 6
months post-natalizumab treatment, none of the 200
patients who switched to alemtuzumab experienced a
relapse. In addition, 43% (69/162) of patients with EDSS
measurements showed improvements in their EDSS scores
and only 1% (2/162) had EDSS worsening. Of patients
with MRI data, 2% (3/160) demonstrated new lesions on
MRI. Generally, AEs were mild and easily managed with
few serious AEs (one death occurred because of urinary
tract infection and unrecognized non-convulsive status
epilepticus) and no cases of PML were detected. The
average washout period during this study was *9 weeks
[79]. Similar results were also observed in a second study
from the same center, which evaluated outcomes in 250
patients who switched to alemtuzumab from prior DMTs,
the majority (66%) having previously received natalizumab
[80].
Despite beneficial outcomes in the absence of a pro-
longed washout period, it is important when switching
from natalizumab to alemtuzumab (or indeed to any other
DMT) to confirm JCV status and exclude any PML carry-
over in JCV-positive patients by MRI and, in some cases,
by cerebrospinal fluid examination for JCV DNA, before
treatment commences. Although JCV status was estab-
lished in the natalizumab switching studies discussed pre-
viously, it was not reported that PML was excluded prior to
initiation of alemtuzumab [79, 80]. This is important, as the
effects of alemtuzumab cannot be reversed in the short
term, and, should carry-over PML develop following
alemtuzumab treatment, it is unlikely that full immune cell
repopulation will have occurred and patients will be unable
to clear the virus. A bridging strategy may be useful in this
case, where an alternative DMT or intravenous corticos-
teroids (methylprednisolone 1000 mg) can be used to
prevent rebound disease, affording the opportunity to fully
exclude PML [78, 81].
3.6 Alemtuzumab in Highly Active Disease
In a pre-specified subgroup analysis of the CARE-MS I and
II studies, alemtuzumab demonstrated beneficial effects in
patients with highly active disease (two or more relapses in
the year prior to randomization and one or more Gd? lesion
at baseline) who were treatment naı¨ve [82] or had relapsed
on prior DMTs [83]. In these highly active disease sub-
groups, alemtuzumab reduced AAR and time to 6-month
CDW by a greater extent than SC IFNb-1a and increased
the number of years free from relapse. In addition, more
patients were free of clinical and MRI disease activity
[82, 83]. This is an important and clinically relevant
observation, as this subgroup represents patients for whom
robust, early intervention would be beneficial (treatment-
naı¨ve patients) or for whom switching therapies may be
most appropriate (patients who had not responded to prior
treatments).
3.7 Levels of Disease Activity Required
for Initiating Alemtuzumab
Despite arguments against providing guidance on specific
patient profiles, some clarification regarding the degree of
disease activity required before considering alemtuzumab
would be helpful. In general, clinical activity, or a com-
bination of both clinical and MRI activity, should be pre-
sent before treatment initiation (Table 6). However, it is
important to consider each patient on a case-by-case basis
and correlate any MRI findings with clinical activity.
Relying solely on MRI findings alone could prove mis-
leading, for example, in patients with pseudotumoral forms
of MS, where single large lesions ([2 cm) mimic other
tumor-like lesions such as neoplasms, infections, or
infarctions [84, 85]. Guidance on how to effectively use
Table 6 Author recommendations for level of disease activity required for use of alemtuzumab
Clinical activity
C2 relapses in previous year
Clinical and MRI activity
1 relapse within the previous year with new MRI activity attributable to MS
1 relapse within the previous year with incomplete recovery associated with an increase of C2 new T2 or Gd
? lesions
Cognitive decline with MRI activity attributable to MS
Patients with breakthrough diseasea (activity on clinical or MRI assessments)
Gd? gadolinium-enhancing, MRI magnetic resonance imaging, MS multiple sclerosis
a Patients with stable disease for several years who suddenly experience C1 relapse with an increase in disability and number of Gd? lesions
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MRI findings to assist treatment decisions should also be
provided to physicians.
The alemtuzumab EU label defines active disease as the
presence of clinical or imaging features but gives no
guidance as to the level of disease activity required before
considering initiating therapy or retreatment [2]. In the
three clinical studies [9, 11, 12], slightly differing criteria
were used to define active disease, and MRI activity was
only used to define active disease in CAMMS223 (Table 1)
[9, 13]. Nevertheless, MRI activity was part of the
retreatment criteria (see footnote to Table 1) applied in the
CAMMS223 clinical trial (Sanofi Genzyme, data on file)
and the CARE-MS extension studies [15].
3.8 Patients Unsuitable for Alemtuzumab
Currently, patients with inactive disease or those stable on
current therapy (as per the approved label) would not be
considered for treatment, and, as alemtuzumab has not
been thoroughly evaluated in progressive MS, it is also not
indicated for use in these patients [2]. Of course, there are
always exceptions, and, while some patients may meet
eligibility criteria as per the EU indication, certain safety
considerations and challenges with frequent post-treatment
monitoring may preclude them from being considered
suitable for treatment. In such instances, a physician’s
experience and knowledge of their patient will prove
invaluable in deciding upon the best approach. Compliance
with the monitoring requirements associated with alem-
tuzumab treatment is vital to ensure identification of AEs
promptly; therefore, a physician’s previous experience will
enable them to make an educated assessment with regard to
their patients’ suitability and likelihood of their adherence
to the strict monitoring requirements. As alemtuzumab
treatment is associated with a potential increased risk of
developing serious infections, patients with signs of
infectious disease may be precluded from initiating treat-
ment until the infection is fully under control or has
resolved [65]. Likewise, given that alemtuzumab may
increase the chance of developing certain cancers (thyroid
cancer, skin cancer [melanoma], lymphoproliferative dis-
orders, and lymphoma) caution should be exercised before
initiating treatment with alemtuzumab in patients with a
pre-existing and/or an ongoing malignancy [2, 86].
3.9 Expectations for Alemtuzumab Treatment
Alemtuzumab is currently considered one of the most
highly effective DMTs available for RRMS and provides
patients with a unique treatment approach that results in
durable efficacy in the absence of continuous treatment.
Nevertheless, despite superior efficacy vs. subcutaneous
IFNb-1a in treatment-naı¨ve patients with active disease,
alemtuzumab, with its long-term safety monitoring
requirements is unlikely to replace the first-line DMTs such
as IFNb, glatiramer acetate, teriflunomide, or DMF in the
near term. Furthermore, given the complex nature of MS,
with both inflammatory and neurodegenerative compo-
nents, it remains to be determined whether alemtuzumab
treatment can achieve permanent remission of MS disease
activity over the very-long term. Extensions to the clinical
trials are currently ongoing, and 4-year follow-up data have
demonstrated that the majority of patients (74% CARE-MS
I; 66% CARE-MS II) have stable or improved disability at
year 4 [7, 8], despite most (74% CARE-MS I; 68% CARE-
MS II) only receiving the initial two courses of alem-
tuzumab [7, 8].
4 Effective Administration of Alemtuzumab
In accordance with the EU label, alemtuzumab treatment
should be supervised by a neurologist experienced in the
treatment of patients with MS [2]. In addition, given the
increased risk of autoimmune AEs during alemtuzumab
treatment, it is encouraged that specialists who are able to
provide treatment for autoimmune conditions be identified
in advance of treatment initiation [2]. Although serious
IARs only occurred in B3% of patients in the clinical trial
setting [9, 11–13, 21, 23, 24], specialists and equipment
required for the management of infusion-related condi-
tions (e.g., hypersensitivity reactions) should also be
available.
To minimize and reduce the severity of IARs, prophy-
lactic antihistamines and antipyretics are recommended
before alemtuzumab infusions [87]. Routine dosages of
antihistamines, such as the non-sedating histamine H1-re-
ceptor antagonists (loratadine or cetirizine) and the H2-
receptor antagonists (ranitidine or famotidine), may be
considered, as well as antipyretics, such as acetaminophen
or ibuprofen. These should be administered the morning of
the alemtuzumab infusion, with a record being made of the
time that the medication was taken [88].
In addition, intravenous corticosteroids may also be
administered immediately prior to treatment on each of the
first 3 days of any treatment course. However, in Italy, a
recent study showed that around 50% of patients require
intravenous corticosteroids (methylprednisolone 1000 mg)
on days 4 and 5 of the first alemtuzumab infusion, as IARs
were not reduced in severity with the standard 3 days of
corticosteroid treatment [89]. This approach is now
becoming more common in European clinics.
Oral prophylaxis with an anti-herpes agent (e.g., acy-
clovir 200 mg twice daily) on the first day of each treat-
ment course and continued for a minimum of 1 month is
also recommended [2, 14].
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Among other common AEs linked to IARs with alem-
tuzumab are an increased heart rate and a reduction in
blood pressure; therefore, vital signs prior to, during, and
for 2 h following the infusion period should be monitored
[2].
Most alemtuzumab-related IARs can be managed with
medical intervention or by slowing or interrupting the
infusion [88]. Although the label recommends that alem-
tuzumab be administered as two annual courses given on 5
consecutive days at baseline and on 3 consecutive days 12
months later, respectively, with each daily infusion lasting
4 h, dosing interruptions (e.g., a missed infusion) or an
extension to the infusion period was permitted in clinical
trials [2, 21, 90]. Infusion interruption in the CARE-MS
studies was rare, with 95% of patients completing the
initial course within 5–7 days and 97% completing the
second course within 3–5 days [21, 90]. In a recent study
using data from CARE-MS I and II, administration of
alemtuzumab infusions over an additional 5 days did not
increase the overall incidence of IARs, affect the extent of
lymphocyte depletion, or reduce treatment efficacy [90].
However, missed doses should not be given on the same
day as a scheduled dose [2]. Patients may also receive
additional courses of alemtuzumab beyond the first two
annual courses, provided 12 months have passed since the
previous course of treatment [2]. Criteria used in the
CAMMS223 (Sanofi Genzyme, data on file) and the
CARE-MS extensions [15] for retreatment may be used as
a guide for when to initiate retreatment (Table 1).
The duration of alemtuzumab infusions may present
some logistical issues, for example, where the patients will
receive treatment. In Europe, this is likely to be in a spe-
cialist hospital-based setting; therefore, in countries with
few MS centers, accessibility could impact access to
treatment.
In clinical trials, most participants received alem-
tuzumab as outpatients, and this may prove more conve-
nient in a real-world setting. For those patients who need to
travel long distances to an MS center, hospitalization may
be a more logical approach, and, in some cases, hospital
admission may provide an opportunity for patients to
receive additional services.
5 Risk Minimization and Patient Monitoring
5.1 Vaccination Prior to Initiating Alemtuzumab
Treatment
The ability to mount effective immune responses to vac-
cines following alemtuzumab has not been studied exten-
sively. However, a small pilot study demonstrated that
alemtuzumab did not impair humoral immunologic
memory with respect to the ability to generate antibodies
against common viruses or the response to recall antigens,
or the ability to mount a humoral immune response against
a novel antigen [91]. The alemtuzumab label recommends
that patients should complete local immunization require-
ments at least 6 weeks before starting therapy [2, 92].
Patients without a history of chicken pox should be tested
and, if necessary, immunized against varicella zoster virus
prior to starting treatment [2]. Immune responses against
live viral vaccines have not been evaluated and current
recommendations state that patients recently initiating
alemtuzumab (as with all DMTs) should not receive live
viral vaccines [2]; ongoing studies are evaluating the use of
live viral vaccines in patients receiving alemtuzumab.
5.2 Alemtuzumab Treatment-Related Risks
In clinical studies, a number of risks were associated with
alemtuzumab treatment, including IARs, infections, and
autoimmune disorders, which led to establishment of an
RMP in the EU (Table 7) and the REMS in the USA
[30, 86]. Global labeling recommends that all patients
receiving alemtuzumab need to be monitored for 48
months following their last alemtuzumab infusion [2, 3].
Data on identified (e.g., autoimmune disorders, including
thyroid disorders, ITP, and glomerulonephropathy) and
potential risks (e.g., malignancy and other autoimmune
disorders, i.e., cytopenias) will be evaluated as per the
RMP and REMS [30, 86].
Monitoring forms a significant and important compo-
nent of alemtuzumab treatment and will be achieved
through planned post-authorization safety studies, reg-
istries (including a pregnancy registry to establish any
effects of alemtuzumab on pregnancy, lactation, and
reproductive toxicity), and routine pharmacovigilance. As
required by the RMP and REMS, the summary of product
characteristics and educational materials (healthcare pro-
fessional guide, prescriber checklist, patient guide, and
alert card) have been made available to communicate the
serious risks associated with the use of alemtuzumab [2].
These materials, in addition to counseling, hopefully will
promote adherence to the monitoring program by high-
lighting the benefit-risk profile and reinforcing the impor-
tance of monitoring among both physicians and their
patients.
Education and training of all medical staff (neurolo-
gists, general practitioners, and nurses) on the practicali-
ties of administering alemtuzumab, particularly with
regard to IARs, are key, so that patients get timely man-
agement if and when IARs occur. However, it is most
important to ensure that patients are informed of the risks
associated with alemtuzumab infusion, so that they can be
reassured that IARs are an expected AE and the chance of
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infusion interruption can be minimized. Patients also need
to be informed and understand the risks of serious
autoimmune disorders, infections, and malignancies and
the measures to minimize them, such as ongoing moni-
toring. A well-informed and educated patient will
understand their responsibility to comply with the long-
term monitoring requirements associated with alem-
tuzumab treatment. A plan, formulated between the
physician and patient for monitoring post-alemtuzumab
infusion is essential, and patients need to be made aware
of the signs and symptoms of possible serious AEs.
Consideration should be given to enrolling patients in
programs such as the Sanofi Genzyme MS one-to-one
program [93] or establishing a monthly e-mail reminder
service to notify them when their monthly blood and urine
tests are due. If potential logistical or social issues are
known at the outset, physicians must consider whether
these patients are suitable for alemtuzumab treatment.
The greatest logistical problem, however, will be ensuring
that those already receiving treatment adhere to the
monitoring program, particularly those who respond well
after two courses of treatment and have no evidence of
active disease.
As part of the RMP and REMS, mechanisms will be in
place to remind patients about their monthly monitoring
appointments and also to ensure that physicians are
informed if tests are missed [30, 86]. It may be pertinent to
implement an active follow-up service, perhaps coordi-
nated through the patient’s general practitioner, to ensure
they are adhering to the monitoring requirements. This may
be particularly important for patients who do not live in
close proximity to a MS center. These approaches will help
facilitate early detection of AEs, increasing the likelihood
of favorable outcomes. The RMP and REMS are dynamic
and will be updated if new information emerges leading to
a significant change in the benefit-risk profile or if an
important pharmacovigilance or risk minimization mile-
stone is reached [2].
5.3 Autoimmune Adverse Events
The RMP and REMS have been designed to ensure early
detection of autoimmune conditions, such as thyroid dis-
orders and, more rarely, ITP, glomerulonephropathies, and
other autoimmune disorders. Testing should begin in all
patients prior to initiation of therapy and continue on a
monthly basis for 48 months following the last infusion
[2, 30].
Thyroid dysfunction is the most commonly reported
autoimmune AE in alemtuzumab-treated patients, with the
thyroid gland being adversely affected in *36% of
patients in a 4-year follow-up of the CARE-MS I and II
trials [94]. Autoimmune thyroid disease may lead to
hyperthyroidism (increased thyroid hormone levels in the
serum with suppressed thyroid-stimulating hormone) or
hypothyroidism and neurologists need to be aware of how
to diagnose and treat these conditions [94]. Typically,
changes in thyroid-stimulating hormone, thyroxine, and tri-
iodothyronine levels are evaluated [95, 96]. In some cen-
ters, thyroid antibodies are also investigated and where
hyper- or hypothyroidism is suspected these cases are
followed up with an ultrasound examination of the thyroid
gland. A recent article by Mahzari et al. presents case
studies for four patients from the CARE-MS trials who
Table 7 Risk management program and mitigation strategy [30, 86]
Mitigation strategy and planned actions
Prior to
treatment
Every month Every 3
months
Education Routine
PV
PASS
Identified risks
ITPa
Test: CBC with differential
9 9 9 9 9
Nephropathiesa
Tests: serum creatinine levels, urinalysis with microscopy
9 9 9 9 9
Thyroid eventa
Test: thyroid function (TSH levels)
9 9 9 9 9
ITP: generally responded to first-line treatment promptly
Nephropathies: no cases recorded in phase III studies (one membranous glomerulonephritis in the extension)
Thyroid events: managed with conventional medications/treatment; surgery was rare (one patient underwent splenectomy during CARE-MS II
extension)
CBC complete blood count, ITP immune thrombocytopenic purpura, PASS Post-Authorization Safety Study, PV pharmacovigilance, TSH
thyroid-stimulating hormone
a Safety monitoring and education for early detection, proposed to continue for 48 months after last alemtuzumab infusion
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developed autoimmune thyroid disease and provides a
comprehensive account of the signs and symptoms to be
aware of [94].
Alemtuzumab-induced thyroid disease is a treatment-
related AE that needs to be recognized, as generally it can
be managed relatively easily with standard-of-care treat-
ments. Management involves differentiating the underly-
ing etiology, e.g., establishing whether this is due to
hypothyroidism or hyperthyroidism and whether Graves’
disease or subacute painless thyroiditis is the cause of
hyperthyroidism. In the case of hypothyroidism, thyroid
hormone replacement therapy should be considered, with
patients monitored every 4–8 weeks to adjust thyroid
hormone dosages. If hypothyroidism develops following
treatment for hyperthyroidism, subacute painless thy-
roiditis should be suspected. Hyperthyroidism following
alemtuzumab treatment is most likely due to Graves’
disease and should be managed initially with anti-thyroid
medication (thionamides); in clinical trials, this approach,
rather than radioactive iodine or thyroidectomy, was
associated with a higher likelihood of remission. Thy-
roidectomy or radioactive iodine would be indicated fol-
lowing failure of anti-thyroid medication. Where subacute
painless thyroiditis is suspected, b-adrenergic blockers or
corticosteroids (severe cases only) may be considered.
Anti-thyroid medications are not applicable in these
patients as thyroid hormone synthesis is already low. An
algorithm for the treatment of patients presenting with
alemtuzumab-induced hyperthyroidism has been pro-
posed by Mahzari et al. [94].
Thyroid disease poses a special risk in women who are
pregnant, and studies are currently underway to investigate
the effect of alemtuzumab on fertility and pregnancy
[2, 97]. Patients should also be instructed on how to rec-
ognize the signs and symptoms of ITP, such as appearance
of small spots on the skin (petechiae), easy bruising, heavy
menstruation, bleeding that takes longer than normal to
stop, or hematoma development, and informed about other
risk factors for autoimmune disease (e.g., smoking and a
family history of autoimmune disease) [98, 99]. If signs of
ITP are observed, patients should have a complete blood
count to determine whether their platelet number has
reduced, and, if ITP is confirmed, the patient should be
immediately referred to a specialist.
In the core clinical trials, ITP was reported in 16 patients
(CAMMS223 [n = 6]; CARE-MS I [n = 3] and CARE-MS
II [n = 7]) and occurred between 1 and 16 months after the
last alemtuzumab infusion. With the exception of the fatal
index case (cerebral hemorrhage), most cases resolved
spontaneously (n = 2), or after treatment with platelet
transfusion, rituximab, steroids and/or intravenous
immunoglobulin, and within 3 months of onset. One
patient from the CARE-MS II study underwent
splenectomy following corticosteroid treatment [12]. In the
extension study, a total of 20 cases of ITP were identified
from patients originating from the CAMMS223 (n = 1),
CARE-MS I (n = 4), and CARE-MS II (n = 15) studies. In
these patients, onset occurred between 4 and 44 months
after the last alemtuzumab infusion and, as with the core
studies, resolved spontaneously (n = 1) or following stan-
dard treatment(s) within 3.2 months (Sanofi Genzyme, data
on file).
More extensive details with regard to ITP cases occur-
ring in the alemtuzumab clinical trial program will be
published elsewhere. All treatment-emergent ITP events
observed in the CARE-MS core and extension studies were
identified through the routine monitoring of platelets and/or
patient reporting of signs or symptoms of ITP established
following the fatal index case in CAMMS223, highlighting
the effectiveness of the monitoring program and educa-
tional materials used routinely in these studies (Sanofi
Genzyme, data on file) [29]. The RMP in the EU and
REMS in the USA are based on these monitoring programs
and educational materials.
Immune nephropathies (including anti-GBM disease)
were detected in 0.3% of patients throughout the clin-
ical trials and extensions [9, 11–13, 15]. Anti-GBM
disease can result in severe kidney damage, thus urine
should be monitored closely [14]. Any detection of
clinically significant changes from baseline in serum
creatinine, hematuria, proteinuria, and urine cell counts
(blood and epithelial cells) and the presence of anti-
GBM antibodies should prompt immediate referral to a
nephrologist, as it is often difficult to determine the
etiology of abnormalities given that urinary tract
infections and hematuria are common occurrences in
patients with MS [31, 99].
Therefore, it is important to ensure that, when estab-
lishing an alemtuzumab service, sufficient infrastructure is
in place that can not only deliver treatment effectively but
also can detect any AEs and manage them effectively via a
predefined network of specialists familiar with alem-
tuzumab and its autoimmune effects.
5.4 Malignancies
Alemtuzumab has a long-term effect on the immune sys-
tem, and, as with other immunomodulatory therapies, the
potential for malignancies is an area of concern. Therefore,
caution is recommended when using alemtuzumab in
patients with a pre-existing and/or ongoing malignancy [2].
Annual malignancy rates during the controlled phases of
the clinical trials were the same for alemtuzumab and SC
IFNb-1a (0.003 events/year), and the risk of all cancers
combined was significantly lower than in the reference
population [100]. The European Medicines Agency also
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concluded that rates of malignancy are no different from
the general population, although firm conclusions regard-
ing the risk could not be drawn [92].
6 Conclusion
This article has discussed the various factors that
physicians and patients in Europe will need to consider
when initiating alemtuzumab treatment. One of the main
questions for physicians considering alemtuzumab will
be to determine which patients are most suitable. The
EU label for alemtuzumab is broad, and defining a
specific patient profile for alemtuzumab may not be
necessary, or even possible. In fact, it may be more
useful to determine which patients are unsuitable for
treatment, such as those with inactive disease or who are
stable on current therapy in accordance with the label, or
for those who may be unable to comply with the mon-
itoring requirements.
Suitable patients fall into two groups, active treatment-
naı¨ve patients and patients only having a partial response to
their current DMT. Alemtuzumab may therefore find use as
an initial therapeutic in treatment-naive patients with active
MS, although the use of a drug with the benefit-risk profile
of alemtuzumab early in the disease course may require a
change in the way physicians balance the risks of disease
worsening against those of treatment. The efficacy of
alemtuzumab in patients with highly active disease sug-
gests that it could also be used as escalation therapy in
patients not fully responding to their current DMTs or in
patients needing to switch therapies for other reasons (e.g.,
safety/tolerability, poor adherence).
Clearly, alemtuzumab has an important place in the MS
treatment paradigm, but it is unlikely to replace first-line
DMTs in the short term. While there are logistical chal-
lenges associated with patient monitoring, these could be
offset by the absence of daily, weekly, or monthly dosing
regimens along with initial and durable efficacy benefits.
Given the complex nature of MS, with both inflamma-
tory and neurodegenerative components, it remains to be
seen whether alemtuzumab treatment can achieve a per-
manent remission of MS disease activity. Nevertheless,
alemtuzumab represents a unique treatment option for
patients with RRMS, providing durable efficacy in the
absence of continuous treatment and, thus, offering
physicians and patients a wider treatment choice for con-
trolling MS.
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